The estimated Net Worth of R Scott Greer is at least 746 千$ dollars as of 9 November 2021. Mr. Greer owns over 12,500 units of Nektar Therapeutics stock worth over 366,718$ and over the last 21 years he sold NKTR stock worth over 0$. In addition, he makes 379,228$ as Independent Director at Nektar Therapeutics.
R has made over 15 trades of the Nektar Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 12,500 units of NKTR stock worth 160,000$ on 9 November 2021.
The largest trade he's ever made was exercising 45,000 units of Nektar Therapeutics stock on 31 August 2021 worth over 571,500$. On average, R trades about 6,059 units every 42 days since 2003. As of 9 November 2021 he still owns at least 293,374 units of Nektar Therapeutics stock.
You can see the complete history of Mr. Greer stock trades at the bottom of the page.
R. Scott Greer is Independent Director of the Company. Mr. Greer currently serves as Managing Director of Numenor Ventures, LLC, a venture capital firm. In 1996, Mr. Greer co-founded Abgenix, Inc., a company that specialized in the discovery, development and manufacture of human therapeutic antibodies, and from June 1996 through May 2002, he served as its Chief Executive Officer. He also served as a director of Abgenix from 1996 and Chairman of the board of directors from 2000 until the acquisition of Abgenix by Amgen, Inc. in April 2006. Prior to Abgenix’s formation, Mr. Greer held senior management positions at Cell Genesys, Inc., a biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development and later as Senior Vice President of Corporate Development, and various positions at Genetics Institute, Inc., a biotechnology research and development company. He currently serves as a member of the board of directors of Inogen, Inc., a medical device company that develops and markets oxygen therapy products. Mr. Greer served as a member of the board of directors of Sientra, Inc., a medical aesthetics company from 2014-2018, Versartis, Inc., an endocrine focused biopharmaceutical company from 2014-2018, Auspex Pharmaceuticals, a biopharmaceutical company developing drugs for patients with movement disorders and other rare diseases from 2014-2015, Sirna Therapeutics, Inc., a biotechnology company, from 2003, and as its Chairman of the board of directors from 2005, through the closing of the acquisition of Sirna by Merck & Co., Inc. in December 2006. From 2001 to 2005, Mr. Greer served as a member of the board of directors of Illumina, Inc., a provider of integrated systems for the analysis of genetic variation and biological function; and from 2001 to 2004, he served as member of the board of directors of CV Therapeutics, Inc., a biotechnology company.
As the Independent Director of Nektar Therapeutics, the total compensation of R Greer at Nektar Therapeutics is 379,228$. There are 13 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of 39,242,200$.
R Greer is 61, he's been the Independent Director of Nektar Therapeutics since 2010. There are 7 older and 11 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
R's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Nektar Therapeutics have traded over 57,608,493$ worth of Nektar Therapeutics stock and bought 90,000 units worth 1,628,550$ . The most active insiders traders include Howard W Robin、Gil M Labrucherie、John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of 36,648$. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth 8,788$.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: